No Data
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $59
TD Cowen analyst Brendan Smith maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 27.3% a
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 494.26K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 18, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on Jun 18, with a total market value of approximately $494.26
Don't Ignore The Insider Selling In Halozyme Therapeutics
We wouldn't blame Halozyme Therapeutics, Inc. (NASDAQ:HALO) shareholders if they were a little worried about the fact that Matthew Posard, the Independent Director recently netted about US$1.0m sellin
Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics(HALO.US) Director Sells US$1.01 Million in Common Stock
$Halozyme Therapeutics(HALO.US)$ Director Posard Matthew L. sold 20,000 shares of common stock on Jun 11, 12, 2024 at an average price of $50.315 for a total value of $1.01 million.Source: Announcemen
Halozyme Therapeutics Insider Sold Shares Worth $1,006,300, According to a Recent SEC Filing
Matthew L. Posard, Director, on June 11, 2024, sold 20,000 shares in Halozyme Therapeutics (HALO) for $1,006,300. Following the Form 4 filing with the SEC, Posard has control over a total of 99,755 sh